Journal article

Implication of the glutamate-cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis

M Fournier, A Monin, C Ferrari, PS Baumann, P Conus, K Do

NPJ SCHIZOPHRENIA | NATURE PUBLISHING GROUP | Published : 2017

Abstract

xCT is the specific chain of the cystine/glutamate antiporter, which is widely reported to support anti-oxidant defenses in vivo. xCT is therefore at the crossroads between two processes that are involved in schizophrenia: oxidative stress and glutamatergic neurotransmission. But data from human studies implicating xCT in the illness and clarifying the upstream mechanisms of xCT imbalance are still scarce. Low glutathione (GSH) levels and genetic risk in GCLC (Glutamate-Cysteine Ligase Catalytic subunit), the gene of limiting synthesizing enzyme for GSH, are both associated with schizophrenia. In the present study, we aimed at determining if xCT regulation by the redox system is involved in ..

View full abstract

Grants

Awarded by Swiss National Science Foundation


Funding Acknowledgements

We thank Helene Moser and Adeline Cottier for their excellent technical assistance with cell culture. We thank Sylvain Pradervand and the Lausanne Genomic Technologies Facility for microarray processing. We thank Michel Cuenod for his precious advices and for reading the manuscript. We are grateful to patients for their enduring participation. This work was supported by the Swiss National Science Foundation (320030_122419 to P.C. and K.Q.D.), National Center of Competence in Research (NCCR) "SYNAPSY-The Synaptic Bases of Mental Diseases" financed by the Swiss National Science Foundation (no 51NF40-158776). We are grateful for support from the Damm-Etienne Foundation, the Banque Lombard Odier &CieSA and Alamaya Foundation. P.S.B. is supported by the Leenaards Foundation.